Corticosteroids and the risk of atrial fibrillation

被引:125
作者
van der Hooft, Cornelis S.
Heeringa, Jan
Brusselle, Guy G.
Hofman, Albert
Witteman, Jacqueline C. M.
Kingma, J. Herre
Sturkenboom, Miriam C. J. M.
Stricker, Bruno H. Ch.
机构
[1] Erasmus Univ, Med Ctr, Dept Epidemiol & Biostat, NL-3000 DR Rotterdam, Netherlands
[2] Erasmus Univ, Med Ctr, Dept Med Informat, NL-3000 DR Rotterdam, Netherlands
[3] Ghent Univ Hosp, Dept Resp Dis, B-9000 Ghent, Belgium
[4] Inspectorate Hlth Care, The Hague, Netherlands
[5] Univ Groningen, Dept Clin Pharmacol, Groningen, Netherlands
关键词
D O I
10.1001/archinte.166.9.1016
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: High-dose ( pulse) corticosteroid therapy has been associated with the development of atrial fibrillation. This association, however, is mainly based on case reports. Methods: To test the hypothesis that high-dose corticosteroid exposure increases the risk of new-onset atrial fibrillation, we performed a nested case-control study within the Rotterdam Study, a population-based cohort study among 7983 older adults. Cases were defined as persons with incident atrial fibrillation between July 1, 1991, and January 1, 2000. Their date of diagnosis was defined as the index date. All noncases within the Rotterdam Study who were alive and eligible on this index date were used as controls. Subsequently, we compared the proportion of cases and controls that received a corticosteroid prescription within 1 month preceding the index date. Corticosteroid exposure was categorized into high-dose exposure ( oral or parenteral steroid at a daily dose >= 7.5 mg of prednisone equivalents) and low-intermediate-dose exposure (< 7.5 mg of prednisone equivalents or inhaled corticosteroids). Results: There were 385 eligible cases of new-onset atrial fibrillation during the study period. The risk of new-onset atrial fibrillation was significantly higher for persons who received a corticosteroid prescription within 1 month before the index date than for those without ( odds ratio [ OR], 3.75; 95% confidence interval [CI], 2.38-5.87). However, only high-dose corticosteroid use was associated with an increased risk ( OR, 6.07; 95% CI, 3.90-9.42), whereas low-intermediate-dose use was not ( OR, 1.42; 95% CI, 0.72-2.82). The association of atrial fibrillation with high-dose corticosteroid use was largely independent of the indication for corticosteroid therapy, since the risk of new-onset atrial fibrillation was not only increased in patients with asthma or chronic obstructive pulmonary disease ( OR, 4.02; 95% CI, 2.07-7.81) but also in patients with rheumatic, allergic, or malignant hematologic diseases ( OR, 7.90; 95% CI, 4.47-13.98). Conclusion: Our findings strongly suggest that patients receiving high-dose corticosteroid therapy are at increased risk of developing atrial fibrillation.
引用
收藏
页码:1016 / 1020
页数:5
相关论文
共 31 条
[1]  
Aslam A K, 2001, Am J Ther, V8, P303, DOI 10.1097/00045391-200107000-00013
[2]   INDEPENDENT RISK-FACTORS FOR ATRIAL-FIBRILLATION IN A POPULATION-BASED COHORT - THE FRAMINGHAM HEART-STUDY [J].
BENJAMIN, EJ ;
LEVY, D ;
VAZIRI, SM ;
DAGOSTINO, RB ;
BELANGER, AJ ;
WOLF, PA .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1994, 271 (11) :840-844
[3]   Quantifying the heart failure epidemic: prevalence, incidence rate, lifetime risk and prognosis of heart failure - The Rotterdam Study [J].
Bleumink, GS ;
Knetsch, AM ;
Sturkenboom, MCJM ;
Straus, SMJM ;
Hofman, A ;
Deckers, JW ;
Witteman, JCM ;
Stricker, BHC .
EUROPEAN HEART JOURNAL, 2004, 25 (18) :1614-1619
[4]   SUDDEN-DEATH AFTER METHYLPREDNISOLONE PULSE THERAPY [J].
BOCANEGRA, TS ;
CASTANEDA, MO ;
ESPINOZA, LR ;
VASEY, FB ;
GERMAIN, BF .
ANNALS OF INTERNAL MEDICINE, 1981, 95 (01) :122-122
[5]   Common carotid intima-media thickness and risk of stroke and myocardial infarction - The Rotterdam Study [J].
Bots, ML ;
Hoes, AW ;
Koudstaal, PJ ;
Hofman, A ;
Grobbee, DE .
CIRCULATION, 1997, 96 (05) :1432-1437
[6]   Reduced lung function and risk of atrial fibrillation in The Copenhagen City Heart Study [J].
Buch, P ;
Friberg, J ;
Scharling, H ;
Lange, P ;
Prescott, E .
EUROPEAN RESPIRATORY JOURNAL, 2003, 21 (06) :1012-1016
[7]   NONRHEUMATIC ATRIAL-FIBRILLATION - RISK OF STROKE AND ROLE OF ANTITHROMBOTIC THERAPY [J].
CAIRNS, JA ;
CONNOLLY, SJ .
CIRCULATION, 1991, 84 (02) :469-481
[8]  
CHIKANZA IC, 1991, BRIT J RHEUMATOL, V30, P392
[9]   Epidemiology and natural history of atrial fibrillation: Clinical implications [J].
Chugh, SS ;
Blackshear, JL ;
Shen, WK ;
Hammill, SC ;
Gersh, BJ .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2001, 37 (02) :371-378
[10]   ANAPHYLAXIS AFTER INTRAVENOUS METHYLPREDNISOLONE ADMINISTRATION [J].
FREEDMAN, MD ;
SCHOCKET, AL ;
CHAPEL, N ;
GERBER, JG .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1981, 245 (06) :607-608